CHINARES PHARMA (03320): Tasly Pharmaceutical Group's net profit attributable to shareholders in 2025 is 1.105 billion yuan, a year-on-year increase of 15.68%.
China Resources Pharmaceutical Group (03320) released unaudited preliminary financial information for the fiscal year ended December 31, 2025 of Tianjin Tasly Pharmaceutical. Tianjin Tasly Pharmaceutical achieved total operating revenue of RMB 8.236 billion, a year-on-year decrease of 3.08%, and achieved a net profit attributable to shareholders of the listed company of RMB 1.105 billion, a year-on-year increase of 15.68%. In terms of the change in revenue, the main reason for the year-on-year decrease in operating revenue is that pharmaceutical business income (mainly chain pharmacy business) decreased by 14.24% year-on-year due to industry policies such as "outpatient pooling".
CHINARES PHARMA (03320) released unaudited preliminary financial information for Tasly Pharmaceutical Group's pharmaceutical business for the year ending December 31, 2025. Tasly Pharmaceutical Group achieved a total operating revenue of RMB 8.236 billion, a decrease of 3.08% year-on-year, and a net profit attributable to shareholders of the listed company of RMB 1.105 billion, an increase of 15.68% year-on-year. In terms of the magnitude of change, the main reason for the year-on-year decrease in operating revenue was the impact of industry policies such as "outpatient planning" on pharmaceutical business income (mainly chain pharmacy business), which decreased by 14.24% year-on-year.
Related Articles
China Railway (00390) appoints Zhao Dianlong as Executive Director.
XUNZHONG (02597) plans to terminate the public issuance of shares to unspecified qualified investors and apply for listing on the Beijing Stock Exchange.
Smart Key International (02590) receives attention from southbound funds on its first day of listing, highlighting the emergence of a window for long-term value positioning.
China Railway (00390) appoints Zhao Dianlong as Executive Director.
XUNZHONG (02597) plans to terminate the public issuance of shares to unspecified qualified investors and apply for listing on the Beijing Stock Exchange.
Smart Key International (02590) receives attention from southbound funds on its first day of listing, highlighting the emergence of a window for long-term value positioning.
